Trial · NCT04154956
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Tusamitamab Ravtansine | 5.39 | 95% Confidence Interval 3.713 to 6.998 | months | |
| Progression-free Survival (PFS) | Docetaxel | 5.85 | 95% Confidence Interval 5.520 to 7.359 | months | |
| Overall Survival (OS) | Tusamitamab Ravtansine | 12.81 | 95% Confidence Interval 11.795 to 14.160 | months | |
| Overall Survival (OS) | Docetaxel | 11.53 | 95% Confidence Interval 8.936 to 15.244 | months | |
| Objective Response Rate (ORR) | Tusamitamab Ravtansine | 21.7 | 95% Confidence Interval 16.04 to 28.26 | percentage of participants | |
| Objective Response Rate (ORR) | Docetaxel | 24.1 | 95% Confidence Interval 18.13 to 30.84 | percentage of participants | |
Time to Deterioration (TTD) in Disease-related Symptoms as Determined by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Lung Cancer-specific Module With 13 Items (EORTC QLQ LC-13) | Tusamitamab Ravtansine | 2.83 | 95% Confidence Interval 2.103 to 4.304 | months | |
Time to Deterioration (TTD) in Disease-related Symptoms as Determined by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Lung Cancer-specific Module With 13 Items (EORTC QLQ LC-13) | Docetaxel | 1.87 | 95% Confidence Interval 1.544 to 2.793 | months | |
| TTD in Physical Function as Determined by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Cancer-specific Module With 30 Items (EORTC QLQ C30) | Tusamitamab Ravtansine | 7.46 | 95% Confidence Interval 5.552 to 15.211 | months | |
| TTD in Physical Function as Determined by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Cancer-specific Module With 30 Items (EORTC QLQ C30) | Docetaxel | 4.17 | 95% Confidence Interval 3.023 to 4.567 | months | |
| TTD in Role Function Measured by EORTC QLQ C30 | Tusamitamab Ravtansine | 5.55 | 95% Confidence Interval 3.713 to 6.308 | months | |
| TTD in Role Function Measured by EORTC QLQ C30 | Docetaxel | 4.17 | 95% Confidence Interval 2.793 to 4.370 | months | |
| Duration of Response (DOR) | Tusamitamab Ravtansine | 11.07 | 95% Confidence Interval 5.158 to 19.844 | months | |
| Duration of Response (DOR) | Docetaxel | 5.75 | 95% Confidence Interval 4.074 to 7.326 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04154956/results